EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Psychological Well‐Being and Depressive Symptoms: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Tsung-Hsuan Hung, Chyi-Rong Chen, Chih-Wei Hsu iD, Andre F Carvalho, Brendon Stubbs, Ping-Tao Tseng, Liang-Jen Wang, Pao-Yen Lin

Human Psychopharmacology: Clinical and Experimental · 2026-05 · 41 (3)

DOI: 10.1002/hup.70041 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 31.03.2026. Verfasst von Tsung-Hsuan Hung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Depression. Die Arbeit nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for metabolic disorders. Howeve, their effects on depressive symptoms and psychological well‐being remain uncertain.

Methods

We conducted a systematic review and meta‐analysis of randomized controlled trials evaluating the effects of GLP‐1RAs on depressive symptoms and psychological well‐being. Random‐effects models were used to calculate standardized mean differences (SMDs). Subgroup and meta‐regression analyses were performed to explore heterogeneity. The protocol was registered with PROSPERO (CRD42024566217).

Results

In total, 25 trials (17,751 participants) evaluated psychological well‐being and 11 trials (1961 participants) evaluated depressive symptoms. GLP‐1RA treatment was associated with a small but significant improvement in psychological well‐being compared with control conditions (SMD = 0.374, 95% CI 0.093–0.656), whereas no significant effect was observed for depressive symptoms (SMD = 0.079, 95% CI −0.024–0.182). Improvements in psychological well‐being were consistently observed in studies using semaglutide, tirzepatide or liraglutide, subcutaneous administration, and in populations with type 2 diabetes mellitus or obesity.

Conclusions

GLP‐1RA treatment was associated with modest improvements in psychological well‐being but not depressive symptoms. These findings should be interpreted cautiously and suggest that any observed psychological benefits are likely indirect, potentially reflecting improvements in metabolic status or general health, rather than direct mood‐improving effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDepressionHumansRandomized Controlled Trials as TopicPsychological Well-BeingSemaglutide

Stichwörter der Autor:innen

depressiondiabetes mellitusglucagon‐like peptide‐1 receptor agonistsmental healthobesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Department of Medical Education, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Occupational Therapy, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
  • Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, Victoria, Australia.
  • Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Department of Sport Science, University of Vienna, Vienna, Austria.

ORCID-Profile: Chih-Wei Hsu

Zitieren

APA

Hung, T. H., Chen, C. R., Hsu, C. W., Carvalho, A. F., Stubbs, B., Tseng, P. T., Wang, L. J., & Lin, P. Y. (2026). Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Psychological Well‐Being and Depressive Symptoms: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Human Psychopharmacology: Clinical and Experimental, 41(3). https://doi.org/10.1002/hup.70041

Vancouver

Hung TH, Chen CR, Hsu CW, Carvalho AF, Stubbs B, Tseng PT, et al. Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Psychological Well‐Being and Depressive Symptoms: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Human Psychopharmacology: Clinical and Experimental. 2026;41(3). doi:10.1002/hup.70041

BibTeX
@article{Hung2026,
  author = {Hung, Tsung-Hsuan and Chen, Chyi-Rong and Hsu, Chih-Wei and Carvalho, Andre F and Stubbs, Brendon and Tseng, Ping-Tao and Wang, Liang-Jen and Lin, Pao-Yen},
  title = {Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Psychological Well‐Being and Depressive Symptoms: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2026},
  volume = {41},
  number = {3},
  doi = {10.1002/hup.70041}
}
Kostenlos starten →